Patents by Inventor Dirk Kosemund
Dirk Kosemund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230201186Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 30, 2022Publication date: June 29, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, Dennis KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, Dirk KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230167078Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: April 20, 2021Publication date: June 1, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Thi Thanh Uyen NGUYEN, Mareike GREES, Nicolas WERBECK, Ulf BOEMER, Benjamin BADER, Detlef STOECKIGT, Dirk KOSEMUND, Rienk OFFRINGA, Corinna LINK, Katrin NOWAK-REPPEL
-
Publication number: 20230148194Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: May 11, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230062100Abstract: The present invention covers aminoquinolone compounds of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Julien LEFRANC, Rienk OFFRINGA
-
Publication number: 20200016159Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives having cyclic substituents in the 3 position, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.Type: ApplicationFiled: September 18, 2017Publication date: January 16, 2020Inventors: Michael HAERTER, Dirk KOSEMUND, Yolanda CANCHO GRANDE, Martina DELBECK, Bernd KALTHOF, Klemens LUSTIG, Frank SUESSMEIER
-
Patent number: 10428083Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.Type: GrantFiled: March 21, 2016Date of Patent: October 1, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Michael Härter, Dirk Kosemund, Martina Delbeck, Bernd Kalthof, Pierre Wasnaire, Frank Süβmeier, Klemens Lustig
-
Patent number: 9962389Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).Type: GrantFiled: April 14, 2017Date of Patent: May 8, 2018Assignee: Bayer Intellectual Property GmbHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
-
Publication number: 20180065981Abstract: The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.Type: ApplicationFiled: March 21, 2016Publication date: March 8, 2018Inventors: Michael HÄRTER, Dirk KOSEMUND, Martina DELBECK, Bernd KALTHOF, Pierre WASNAIRE, Frank SÜßMEIER, Klemens LUSTIG
-
Patent number: 9902716Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). R2 represents the group (a).Type: GrantFiled: October 13, 2015Date of Patent: February 27, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
-
Patent number: 9884849Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: October 14, 2015Date of Patent: February 6, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
-
Patent number: 9877954Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: April 3, 2017Date of Patent: January 30, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn
-
Patent number: 9856242Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: March 12, 2015Date of Patent: January 2, 2018Assignee: Bayer Pharma AktiengesellscaftInventors: Dirk Kosemund, Ulrich Lücking, Arne Scholz, Gerhard Siemeister, Philip Lienau
-
Patent number: 9770445Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: July 3, 2014Date of Patent: September 26, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Dirk Kosemund, Ulrich Lücking, Arne Scholz, Gerhard Siemeister, Philip Alexander Lienau
-
Publication number: 20170226092Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). R2 represents the group (a).Type: ApplicationFiled: October 13, 2015Publication date: August 10, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Dirk KOSEMUND, Ulrich LÜCKING, Gerhard SIEMEISTER, Arne SCHOLZ, Philip LIENAU
-
Publication number: 20170217949Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).Type: ApplicationFiled: April 14, 2017Publication date: August 3, 2017Applicant: Bayer Intellectual Property GmbHInventors: Ulrich LÜCKING, Rolf BOHLMANN, Arne SCHOLZ, Gerhard SIEMEISTER, Mark Jean GNOTH, Ulf BÖMER, Dirk KOSEMUND, Philip LIENAU, Gerd RÜHTER, Carsten SCHULTZ-FADEMRECHT
-
Publication number: 20170217938Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: October 14, 2015Publication date: August 3, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Dirk KOSEMUND, Ulrich LÜCKING, Gerhard SIEMEISTER, Arne SCHOLZ, Philip LIENAU
-
Publication number: 20170202815Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich LÜCKING, Niels BÖHNKE, Arne SCHOLZ, Philip LIENAU, Gerhard SIEMEISTER, Ulf BÖMER, Dirk KOSEMUND, Rolf BOHLMANN, Ludwig ZORN
-
Patent number: 9708293Abstract: The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: October 16, 2013Date of Patent: July 18, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn
-
Patent number: 9676766Abstract: The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: November 17, 2010Date of Patent: June 13, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Volker Schulze, Marcus Koppitz, Dirk Kosemund, Hartmut Schirok, Benjamin Bader, Philip Lienau, Antje Margret Wengner, Hans Briem, Simon Holton, Gerhard Siemeister, Stefan Prechtl, Ulf Bömer
-
Patent number: 9670202Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: GrantFiled: June 3, 2014Date of Patent: June 6, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hartmut Schirok, Volker Schulze, Dirk Kosemund, Hans Briem, Benjamin Bader, Ulf Bömer, Antje Margret Wengner, Gerhard Siemeister, Philip Lienau